@article{oai:repository.lib.tottori-u.ac.jp:00007684,
 author = {杉原, 誉明 and Sugihara, Takaaki and 磯本, 一 and Isomoto, Hajime},
 issue = {1-3},
 journal = {米子医学雑誌, The Journal of the Yonago Medical Association},
 month = {May},
 note = {03446, 01082, The clinical management for disseminated intravascular coagulation （DIC） is quite different from overseas. In Japan, once a clinician diagnoses DIC, antithrombin III （AT-III） or recombinant thrombomodulin（ rh-TM） is usually administered; however, in the United States, no specific medication is used for DIC. The difference originated from the guidelines. There is no description of specific treatment for DIC in the global guidelines. Japanese researchers historically contributed to this field, and Japan has long been leading the establishment of clinical diagnostic criteria. Although there is no firm evidence of the treatment options, AT-III and rh-TM are weakly recommended in severe conditions in the Japanese guideline. The reason would be the difference in the concept of costeffectiveness between Japan and other countries. The global guidelines are intended to be used in any country regardless of economic background. Clinicians in Japan should pay more attention to patients’ eligibility for DIC treatment.},
 pages = {10--21},
 title = {DICを再考する：なぜ米国ではDICを治療しないのか？},
 volume = {74},
 year = {2023},
 yomi = {スギハラ, タカアキ and イソモト, ハジメ}
}